Poslední aktualizace :
08/05/2024
Rakovina drog   Dactinomycin  
Injekce
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy Pdf
   Chemický vzorec  

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cosmegen Argentina, Austrálie, Finsko, Francie, Írán, Itálie, Kanada, Malajsie, Mexiko, Norsko, Nový Zéland, Rakousko, Švédsko, Švýcarsko, USA, ÿecko
Cosmegen Lyovac Irsko, Rumunsko, Velká Británie
Dacilon Chile, Indie, Peru
Dacmozen Indie
Dactino Indie
Dactinomicina Chile, Ekvádor, Kolumbie, Peru
Dactinomycin Nový Zéland
Lyovac Cosmegen Belgie, Lucembursko, NÏmecko, Nizozemsko
Odkazy   Injekce   Odkazy : Dactinomycin  
Typ Uveřejnění
3 Noviny Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84 Noviny Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Noviny Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Noviny Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Noviny Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Noviny Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 Noviny Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Noviny Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Noviny Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492 Noviny Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
729 Noviny Rusmin S, Welton S, DeLuca P, DeLuca PP.
Effect of inline filtration on the potency of drugs administered intravenously.
Am J Hosp Pharm 1977 ; 34: 1071-1074.
857 Noviny Kanke M, Eubanks JL, DeLuca PP.
Binding of selected drugs to a “treated” inline filter.
Am J Hosp Pharm 1983 ; 40: 1323-1328.
905 Noviny Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1178 Noviny Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL.
Stability and compatibility of antitumor agents in glass and plastic containers.
Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322 Noviny Ennis CE, Merritt RJ, Neff DN.
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients.
JPEN 1983 ; 7: 156-158.
1410 Noviny Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Noviny Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
4153 Laboratoř Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics
Orphan Europe (UF) Limited 2014

  Mentions Légales